Pancreatic cancer

Wilmington, Delaware, United States, June 17, 2023 (GLOBE NEWSWIRE) -- The global paclitaxel injection market stood at US$ 811.0 million in 2022, and the global market is projected to reach US$ 484.5 million by 2031. The global industry…

26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering               Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company…

<!-- Name:DistributionId Value:1000821761 --> <!-- Name:NewsArchiveOrgTags Value:Financial#Financial Releases;General#General Releases -->…

<!-- Name:DistributionId Value:1000821353 --> <!-- Name:NewsArchiveOrgTags Value:Financial#Financial Releases;General#General Releases -->…

<!-- Name:DistributionId Value:1000810748 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8752648 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:5557 -->…

<!-- Name:DistributionId Value:8746673 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

OCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune…

Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical Development for Cancer MIRAMAR,…

Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat in patients with anemia of…